Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct-Dec;48(4):373-378.
doi: 10.12865/CHSJ.48.04.02. Epub 2022 Dec 31.

Immunoexpression of Claudin 4 in Gastric Adenocarcinomas

Oana Iulia Crețu  1 , Mioara Desdemona Stepan  2 , Mirela Marinela Florescu  3 , Alex Emilian Stepan  3
Affiliations

Immunoexpression of Claudin 4 in Gastric Adenocarcinomas

Oana Iulia Crețu et al. Curr Health Sci J. 2022 Oct-Dec.

Abstract

Disturbance of the intercellular adhesion system represents a basic biomolecular mechanism in gastric carcinogenesis. Claudin 4 is member of a protein family involved in maintaining homeostasis and epithelial integrity. In this study, we analyzed the immunoexpression of Claudin 4 in 58 cases of gastric adenocarcinomas, in relation to the main histopathological parameters of aggressiveness, the reactions obtained being evaluated through the intensity of the reactions and the number of positive cells. Positive membranous reactions of Claudin 4 were observed in all cases, in tumor cells and some stromal elements, but in some high grade gastric adenocarcinomas also cytoplasmic immunostaining was present. Claudin 4 high scores were associated with tubular, tubulopapillary and hepatoid adenocarcinomas, of low grade and in early stages, aspects that suggest the usefulness of the marker in evaluating the aggressiveness of gastric epithelial tumors.

Keywords: Claudin 4; Gastric adenocarcinomas; histopathological parameters.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Gastric adenocarcinoma, Claudin 4 immunostaining, x40. A. Tubular adenocarcinoma. B. Tubulopapillary adenocarcinoma. C. PCC-SRC. D. Hepatoid adenocarcinoma.
Figure 2
Figure 2
Gastric adenocarcinoma, Claudin 4 immunostaining, x40. A. Low grade adenocarcinoma. B. High grade adenocarcinoma.
Figure 3
Figure 3
Distribution of cases in relation to Claudin 4 immunoexpression and tumor type (A), tumor grade (B) and tumor stage (C).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
    1. Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric Cancer: Where Are We Heading. Dig Dis. 2020;38(4):280–285. - PubMed
    1. Liu W, Li M. The role of claudin-4 in the development of gastric cancer. Scand J Gastroenterol. 2020;55(9):1072–1078. - PubMed
    1. Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37(35):4769–4780. - PMC - PubMed
    1. Moris D, Schizas D, Michalinos A, Kanavidis P, Dimitrokallis N, Alexandrou A, Misiakos E, Liakakos T. The expression of Claudin-4 in gastric cancer tissue: A single center experience. J BUON. 2017;22(2):403–409. - PubMed

LinkOut - more resources